Pfizer, Inc. (NYSE:PFE) has been given an average rating of “Hold” by the twenty-two brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $37.29.

PFE has been the subject of several recent analyst reports. Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and decreased their target price for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Morgan Stanley restated a “neutral” rating and set a $38.00 target price on shares of Pfizer in a research note on Thursday, April 6th. Vetr downgraded Pfizer from a “hold” rating to a “sell” rating and set a $33.45 target price for the company. in a research note on Thursday, March 2nd. Barclays PLC restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Finally, BMO Capital Markets restated a “hold” rating and set a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th.

Pfizer (NYSE PFE) traded up 0.32% during midday trading on Friday, reaching $34.17. The company’s stock had a trading volume of 30,046,310 shares. The stock has a 50 day moving average of $32.70 and a 200 day moving average of $33.07. Pfizer has a 52 week low of $29.83 and a 52 week high of $37.39. The firm has a market capitalization of $203.92 billion, a PE ratio of 28.76 and a beta of 1.02. Pfizer also was the recipient of some unusual options trading on Tuesday. Investors acquired 1,389 call options on the stock. This represents an increase of approximately 135% compared to the average daily volume of 590 call options.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The firm had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter in the prior year, the company earned $0.67 EPS. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. On average, equities research analysts predict that Pfizer will post $2.55 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.75%. Pfizer’s payout ratio is presently 108.48%.

Institutional investors have recently modified their holdings of the company. Psagot Investment House Ltd. boosted its position in shares of Pfizer by 0.8% in the fourth quarter. Psagot Investment House Ltd. now owns 195,830 shares of the biopharmaceutical company’s stock worth $6,361,000 after buying an additional 1,511 shares during the last quarter. Mission Wealth Management LLC boosted its position in shares of Pfizer by 2.1% in the fourth quarter. Mission Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $1,130,000 after buying an additional 704 shares during the last quarter. First Command Bank bought a new position in shares of Pfizer during the fourth quarter worth about $324,000. Mascoma Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter worth about $560,000. Finally, Harbor Advisors LLC bought a new position in shares of Pfizer during the fourth quarter worth about $616,000. 70.80% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Pfizer, Inc. (PFE) Receives Average Rating of “Hold” from Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/23/pfizer-inc-pfe-receives-average-rating-of-hold-from-brokerages-2.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.